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Bacterial colonisation and biofilm formation onto orthopaedic devices are difficult to eradicate. In most cases infection is treated
by surgical removal of the implant and cleaning of the infected area, followed by extensive treatment with broad-spectrum
antibiotics. Such treatment causes great discomfort, is expensive, and is not always successful. In this study we report on the
release of vancomycin through polyethersulfone membranes from channels in cementless titanium-alloy cubes. The cubes were
constructed with LaserCUSING from Ti6Al4V ELI powder. Vancomycin was released by non-Fickian anomalous (constraint)
diffusion. Approximately 50% of the vancomycin was released within the first 17 h. However, sustained delivery of vancomycin for
100 h was possible by reinjecting the channels. Refillable implants may be a novel way to control postoperative infections.
1. Introduction
Bacterial infection is one of the greatest challenges in
orthopaedic surgery [1–3]. Although the infection rate
reported for total hip replacement (THR) surgery is less than
1%, the number of patients that are receiving implants is
increasing [4]. This is also the case in total hip arthroplasty
(THA) [1, 2, 5]. In most cases, infections associated with
revision surgeries are caused by Staphylococcus aureus that
forms a biofilm on the surface of the implants [6, 7]. The
biofilm protects the bacteria against antibiotics and the
host’s immune system [8–10], which provides an additional
challenge in the treatment of infections. Infection is usually
controlled by removing the implant and extensive treatment
of the infected site with broad-spectrum antibiotics [3, 11].
In several studies, the surfaces of implants were coated
with an antimicrobial layer, or antimicrobial compounds
were incorporated in the implants [12]. Customised implants
were produced by using direct metal laser sintering (DMLS),
selective laser melting (SLM), and electron beam melting
(EBM) in metal additive manufacturing (AM) (Table 1).
Femoral stems that are used in THR are largelymanufactured
from wrought material, using subtractive processes [13, 14].
Inmost studies conducted on implantswith antimicrobial
features bacterial infection could be controlled, but only for
a short time. One of the major problems was the rapid
decline in the activity levels of the antimicrobial agent [12]. A
decrease in antibiotic activity levels belowminimal inhibitory
concentration (MIC)may lead to the selection of strains resis-
tant to the specific antibiotic [15]. The ideal is thus to develop
an implant that would release antibiotics in a controlled
manner and at concentrations above MIC levels for as long
as possible. To achieve the desired rate at which the antibiotic
diffuses from the implant into the plasma, the geometric
features of the implant would have to be simple and easy
to manufacture. Additive manufacturing with layer-by-layer
deposition of metal is perhaps the best technique to use [16].
Drug release depends on the physicochemical properties
of the solutes, the structural characteristics of the material,
and the possible interactions between these factors [17].
The three major drug release mechanisms are Fickian-,
constraint-, and zero-order diffusion [18]. In Fick’s model,
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Table 1: Additive metal (AM) medical implants in clinical use.
Company AM Type Surgical application Material Year Reference
Stanmore Implants
Worldwide Ltd
DMLSa and
EBMb Pelvic reconstruction Ti-6Al-4V
d 2010 [23]
Layerwise SLMc Facial reconstruction Ti-6Al-4V 2012 [24]
Adler Ortho EBM Acetabular cups Ti-6Al-4V 2007 [25]
Lima-Lto EBM Acetabular cups Ti Grade 2 2007 [25]
Exactech EBM Acetabular cups Ti-6Al-4V 2010 [25, 26]
Advanced Medical Technologies EBM Lumbar cage Ti Grade 2 2009 [25, 27]
aDirect metal laser sintering.
bElectron beam melting.
cSelective laser melting.
dTitanium alloy.
molecules migrate from a high concentration to regions of
low concentration, with a magnitude proportional to the
concentration gradient and in linear relationship with time
[18].Thismeans the drug relaxation time (𝑡
𝑟
) has to be greater
than the solvent diffusion time 𝑡
𝑑
[19]. The drug is thus
released independently from its concentration. Release of a
drug at a constant rate is defined as zero-order diffusion.This
type of diffusion provides the best control in drug release,
ensuring absolute control over plasma concentrations and
the frequency at which the drug has to be administered. An
implant with controlled-release delivery should thus dispense
the drug at a predetermined rate over a certain period. If
𝑡
𝑟
≈ 𝑡
𝑑
, the drug is released anomalously [19] and thus it is
not at a constant rate.
In this study, vancomycin and gentamicin were used
as model antibiotics. Vancomycin was chosen due to its
use in the treatment of infections caused by methicillin-
resistant strains of S. aureus (MRSA). Palacos R+G bone
cement, containing 12.5mg/g gentamicin (Heraeus Medical
GmbH,Wehrnheim, Germany), was chosen since it has FDA
approval for revision surgeries. Channels in titanium-alloy
cubes were filled with vancomycin and then sealed with a
low-molecular-weight cut-off polyethersulfone membrane.
In another experiment, the channels were filled with Palacos
R+G bone cement.Themechanism of drug release across the
polyethersulfonemembraneswas determined by applying the
Korsmeyer-Peppas equation [20, 21] for release from a thin
slab:
𝑀
𝑡
𝑀
∞
= 𝐾𝑡
𝑛
, (1)
where 𝑀
𝑡
= the cumulative mass of the drug released at
time 𝑡 and 𝑀
∞
= the cumulative mass released at infinity.
𝐾 = the release rate constant (units 𝑡−𝑛), which takes into
consideration the structural and geometrical characteristics
of the drug and the polymer releasing the drug. 𝑛 = the
diffusion exponent that defines the mechanism of release
in the obtained profile. If 𝑛 ≤ 0.5, the drug is released
freely from the titanium-alloy cubes [22]. If 𝑛 > 0.5, but
<1.0, drug release is anomalous and indicative of diffusion
under constraint; that is, the pore sizes restrict the release
of the molecules [22]. In the case of the latter, molecules
migrate in a nonlinear fashion over time and are influenced
by interactions between the liquid and the solid phase [22],
for example, the polyethersulfone membrane. If 𝑛 = 1.0,
release is, according to a case-II diffusion, also known as zero-
order release [22]. If 𝑛 > 1.0, release is classified as a super
case-II diffusion [22].
2. Materials and Methods
2.1. Design and Filling of Titanium-Alloy Cubes. Titanium-
alloy cubes (15 × 15 × 12mm, Figure 1) were manufactured
from Ti6Al4V ELI powder (Concept Laser GmbH, Licht-
enfels, Germany), with a particle size distribution of 38 to
55 𝜇m, on a M2 CUSING machine (Concept Laser GmbH).
The channels were 3.5mm in diameter and were centred
perpendicular to the six surfaces (Figure 1(a)). The channel
openings on the surface of the cube were 6mm in diameter
and 2mm deep. The titanium-alloy cubes were autoclaved
and cooled down to 25∘C in a laminar flow cabinet.
Polyethersulfonemembrane discs 8mm in diameter, with
a molecular cut-off of 5000Da (YMMT 3000, Synder Filtra-
tion, Vacaville, CA), were placed over each of the four vertical
channel openings and the edges glued to the titanium-alloy
surface by applying a thin layer of waterproof epoxy adhesive
(Figure 1(b)). The membranes were then prewetted for 6 h by
injecting 60% (v/v) phosphate buffered saline (PBS, pH 7.4)
with 40% (v/v) ethanol, refilling the reservoirs as needed to
maintain continuous wetting. The ethanol lowered the sur-
face tension of the membranes and prevented the formation
of air bubbles. The membrane tension was kept by fixing a
sterile stainless steel washer (6mm inner diameter) over the
membrane with epoxy adhesive (Figure 1(c)). The bottom
opening of the vertical channel in the cube was sealed with
commercially available antifungal clear silicone. Vancomycin
HCl (Sigma Aldrich, St Louis, MO) was dissolved in sterile
PBS to 2.5mg/mL.The channels in each cube were filled with
400 𝜇L (1.0mg) vancomycin. The open end of the vertical
channel was covered with parafilm.
In a separate experiment, the titanium-alloy cubes were
autoclaved and cooled in a laminar flow cabinet and the
channels filled with Palacos R+G bone cement (ALBC),
containing gentamicin. The Palacos R+G bone cement was
prepared under atmospheric pressure in a monomer-to-
polymer ratio of 1mL to 2 g, according to the manufacturer’s
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Figure 1: (a) Titanium-alloy cube with internal channels, (b) membranes fixed to vertical channel openings, and (c) membranes fixed to
stainless steel washers.
instructions. The two parts were mixed with a spatula for
30 sec and left for 60 sec to set.The cubes with ALBCwere left
to set for 30min in a laminar flow cabinet with an ultraviolet
light (254 nm wavelength). Protruding cement was filled off
with a sterile file.
2.2. Testing of Antimicrobial Properties. Vancomycin-filled
titanium-alloy cubes were placed in a closed beaker with
16mL sterile PBS (pH 7.4) and placed on an orbital shaker
(7 rpm) at 37∘C. After 1, 3, 5, 8, 16, 24, and 43 h, the cubes were
aseptically removed, 1mL PBS was withdrawn, and stored
in an Eppendorf tube at −20∘C. The rest of the PBS was
discarded and the beaker thoroughly rinsed with sterile PBS.
The cubeswere placed back in the beakerwith a fresh solution
of 16mL sterile PBS. Sink conditionswere used to ensure one-
directional diffusion of vancomycin from the cubes into PBS.
At two time points during the experiment (after 33 and 57 h),
the vancomycin solution in each of the cubes was replaced
with 400 𝜇L freshly prepared vancomycin. This was done to
determine the effect of multiple doses.
At the end of the experiment the PBS samples were
thawed, filtered, and transferred to glass autosampler vials
(Chromacol, Herts, United Kingdom), using 17mm diameter
polyvinylidene fluoride (PVDF) disposable syringe filters
with a pore size of 0.2𝜇m (Chromacol). Vancomycin was
detected by reverse-phase high performance liquid chro-
matography (RP-HPLC), based on the method specified in
the vancomycin hydrochloride monograph of British Phar-
macopoeia [28]. A Finnigan Surveyor Plus HPLC (Thermo
Electron Corporation, Waltham, MA) and a Surveyor Plus
pump coupled with an autosampler were used.
Twentymicroliters of the samplewas injected. A Surveyor
UV/Vis Plus detector (set at a wavelength of 280 nm) was
used, as described by British Pharmacopoeia [28].Themobile
phase consisted of HPLC-grade acetonitrile (AcN) (Merck)
with 0.1% trifluoroacetic acid (TFA) andMilli-Qwater (EMD
Millipore) with 0.1% TFA. A C18 Thermo Scientific Hyper-
sil GOLD reverse-phase chromatographic column (Thermo
Fisher Scientific, Waltham, MA) of 100mm × 4.6mm and
5 𝜇msilica particle sizewas used.The gradients used are listed
in Table 2. Preliminary runs revealed an average retention
time of 4.67 ± 0.02min for 14 injections.
Vancomycin HCl standards injected into the HPLC were
5.0, 12.5, 25.0, 50.0, 125.0, and 250.0 𝜇g/mL PBS. Integration
of the detection peaks as well as linear regression was
performed automatically by the software ChromQuest 4.2.34
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Table 2: Mobile phase elution program used in RP-HPLC.
Time
(min)
% Milli-Q
(0.1% TFA)
% AcN
(0.1% TFA) Elution type
0-1 95 5 Isocratic
1–5 95–0 5–100 Linear gradient
5-6 0 100 Isocratic
6–11 0–95 100–5 Linear gradient
11-12 95 5 Isocratic
version 3.1.6 (Thermo Electron Corporation). Linear regres-
sion was confirmed by manual calculations. Data recorded
for the first 60% cumulative release values were fitted to
the Korsmeyer-Peppas model. The data were evaluated using
a two-tailed Student’s 𝑡-test (𝑃 = 0.05) for independent
samples with the assumption of equal variances. A null
hypothesis indicated that the means are equal. Failure to
reject the null hypothesis therefore statistically validates the
fitted model to represent the same population as that of the
recorded values. Simple linear regressionwas used to evaluate
the linearity of the data when plotted against the linearised
Korsmeyer-Peppas model.
Diffusion of gentamicin from the Palacos R+G ALBC
was tested by monitoring the growth inhibition of S. aureus.
The ALBC-filled cubes were placed on the surface of sterile
Brain Heart Infusion (BHI) agar (Biolab Diagnostics, Biolab,
Midrand, South Africa). Staphylococcus aureus strain Xen
36 and the methicillin-resistant strain Xen 31 (both from
Caliper Life Sciences, Hopkinton, MA) were cultured sepa-
rately in BHI broth (Biolab) at 37∘C for 24 h to an optical
density of 0.3 at 595 nm. This corresponded to log
10
6.7 ±
0.1 CFU/mL. Twenty microliters of each cell suspension was
individually mixed with 20mL melted BHI agar (Biolab),
poured over the vancomycin-filled titanium-alloy cubes, and
incubated at 37∘C for 24 h. The medium was supplemented
with 0.001% (w/v) cycloheximide (Sigma Aldrich) to prevent
fungal growth. Images of the plates were taken; the cubes
were aseptically removed, sterilised by wiping with 70% (v/v)
ethanol (v/v), and left to dry in a sterile flow cabinet. The
cubes were then transferred to a fresh plate with BHI agar
and, as before, covered with S. aureus Xen 36 or Xen 31
imbedded in BHI agar. The plates were examined for growth
inhibition after 24 h of incubation at 37∘C. The cubes were
removed and sterilised and the process was repeated until no
zones of growth inhibition were observed. The surface area
of the inhibition zones (excluding the area of the cube) was
calculated and expressed as mm2.
3. Results and Discussion
Release of vancomycin from the cubes was without any initial
burst (Figure 2). Lack of a burst release is characteristic of
zero- or near zero-order diffusion [29]. Sustained near zero-
order diffusion provides prolonged drug delivery as long as
the drug remains stable.
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Figure 2: Cumulative mass of vancomycin released from titanium-
alloy cubes. Values plotted are from six experiments.
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Figure 3: Cumulative percentage of vancomycin released from
titanium-alloy cubes. Values are the average from six experiments.
Standard deviations are shown.
To determine the values of 𝐾 and 𝑛, the Korsmeyer-and-
Peppas model was linearized:
𝑀
𝑡
𝑀
∞
= 𝐾𝑡
𝑛
,
ln(
𝑀
𝑡
𝑀
∞
) = ln (𝐾𝑡𝑛) ,
(2)
ln(
𝑀
𝑡
𝑀
∞
) = ln𝐾 + ln (𝑡𝑛) . (3)
A high degree of linearity (𝑅2 = 0.99) was obtained
when the data were plotted using (3). The values obtained
for 𝐾 and 𝑛 were 6.46 and 0.73, respectively. Since the 𝑛-
value was higher than 0.5, but less than 1.0, the release of
vancomycin is defined as non-Fickian and typical of that
observed for anomalous (constraint) diffusion. Fitting of the
data into the Korsmeyer-and-Peppas model at different time
points is presented in Table 3 and is plotted in Figure 3.
An estimated 50.54% of vancomycin was released within
the first 17 h (Figure 3) and falls within the 60% cut-
off value for the diffusion approximation model developed
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Figure 4: (a) Growth inhibition of S. aureus Xen 36 as gentamicin diffused from Palacos R+G ALBC-filled titanium-alloy cubes. Inhibition
zones were recorded after 24 h (A), 48 h (B), 72 h (C), and 96 h (D). (b) Sizes of growth inhibition zones (in mm2) at each of these time points.
Values are the average from six experiments. Standard deviations are shown.
by Korsmeyer-and-Peppas [19]. Sustained delivery of van-
comycin over a longer period was possible by repeated filling
of the cubes. From a practical point, the antibiotic levels in a
titanium-alloy implant may be regulated by reinjection until
infection is under control.
Gentamicin diffused from Palacos R+G ALBC-filled
cubes for 360 h, as recorded by growth inhibition of S. aureus
Xen 36 (not shown). Clear zones of growth inhibition against
strain Xen 36 were recorded for up to 96 h (Figure 4(a)).
Most of the gentamicin was released after 24 h, as indicated
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Table 3: Fitting of Korsmeyer-Peppas model to first 60% of cumulative drug release.
Time (hours) % observed cumulative release % estimated cumulative release Square error Sum of square errors 𝑃 value
1 6.34 6.46 0.01
2.01 0.974 18.26 17.67 0.35
9 32.96 31.85 1.24
17 49.90 50.54 0.42
by a large zone of growth inhibition (Figure 4(a)(A)), cor-
responding to a surface area of 725mm2 (Figure 4(b)). The
steady decline in growth inhibition zones over the next 24 h
(Figures 4(a)(B) and 4(b)) indicated that gentamicin was
released at a much slower rate. Zone sizes recorded at 72
and 96 h (Figures 4(a)(C) and 4(a)(D), resp.) ranged from
250 to 160mm2 (Figure 4(b)), indicating that gentamicin was
released at a more constant rate, but at less active levels. The
high reduction in inhibition zone sizes after the first 24 h is
typical of burst release. According to Poelstra et al. [29], 6-to-
8 h after surgery is themost critical period to prevent bacterial
infection. Based on the data presented here, diffusion of
gentamicin from Palacos R+G into titanium-alloy cubes may
control S. aureus infection for as long as 96 h. Staphylococcus
aureus Xen 31 was less sensitive to gentamicin and growth
inhibition was recorded for only the first 48 h (not shown).
This corresponds to results published with cement discs [30].
As with most bacterial species, resistance to antibiotics is
strain-specific [23]. This has to be taken into account in
determining the treatment period of postoperative infections.
4. Conclusions
Diffusion of vancomycin and gentamicin from titanium-
alloy cubes, prepared from LaserCUSING of Ti6Al4V ELI
powder, indicated that it is possible to introduce the technol-
ogy in implants and prevent secondary bacterial infections.
Designing of an implant that allows repeatable filling with
antibioticsmay keep levels well aboveMIC for longer periods,
thereby lowering the risk of strains developing resistance to
antibiotics. The release of vancomycin through polyethersul-
fone membranes by constraint diffusion implies an interplay
between Fickian diffusion and polymer relaxation. This
research provides a basis for more detailed and specialised
studies on developing a fully functional implant prototype.
The technologymay be extended to include other compounds
such as anti-inflammatories. The invention could lead to a
significant reduction in operating theatre time and medical
costs.
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